Treatment of Pituitary Dwarfism with Methionyl Human Growth Hormone in Japan

16Citations
Citations of this article
5Readers
Mendeley users who have this article in their library.

Abstract

Sixty-two patients with pituitary dwarfism were treated with three different preparations of methionyl hGH (m-hGH) for 3 to 14 months. They were given 0.5 IU/kg/week intramuscularly. The growth rate during treatment with the three different preparations was the same for each and increased from 3.5 ±0.9 to 8.2± 1.7 cm/year. A high incidence of hGH antibody formation was observed following the treatment, but the titer of antibody was decreased according to the purity of m-hGH preparations. At the end of 12 month treatment with a highly purified preparation (Somatonorm III), 76.2% of the patients had hGH antibody. However, the presence of antibodies did not affect the growth rate except in one patient. No clinical or laboratory side-effects were observed following the treatment with m-hGH. Thus, m-hGH was considered to be useful for the treatment of GH deficient children. © 1986, The Japan Endocrine Society. All rights reserved.

Cite

CITATION STYLE

APA

Takano, K., Shizume, K., Hizuka, N., Okuno, A., Umino, T., Kobayashi, Y., … Ono, S. (1986). Treatment of Pituitary Dwarfism with Methionyl Human Growth Hormone in Japan. Endocrinologia Japonica, 33(5), 589–596. https://doi.org/10.1507/endocrj1954.33.589

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free